company background image
5243

Orchid Pharma BSE:524372 Stock Report

Last Price

₹325.45

Market Cap

₹13.3b

7D

4.4%

1Y

-23.9%

Updated

05 Oct, 2022

Data

Company Financials
524372 fundamental analysis
Snowflake Score
Valuation3/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

524372 Stock Overview

Orchid Pharma Limited, a pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India.

Rewards

Trading at 31.2% below our estimate of its fair value

Earnings have grown 30.2% per year over the past 5 years

Risk Analysis

No risks detected for 524372 from our risk checks.

Orchid Pharma Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Orchid Pharma
Historical stock prices
Current Share Price₹325.45
52 Week High₹468.90
52 Week Low₹260.20
Beta0
1 Month Change3.06%
3 Month Change15.61%
1 Year Change-23.89%
3 Year Changen/a
5 Year Changen/a
Change since IPO1,708.06%

Recent News & Updates

Shareholder Returns

524372IN PharmaceuticalsIN Market
7D4.4%5.0%1.4%
1Y-23.9%-11.3%-1.7%

Return vs Industry: 524372 underperformed the Indian Pharmaceuticals industry which returned -11.3% over the past year.

Return vs Market: 524372 underperformed the Indian Market which returned -1.7% over the past year.

Price Volatility

Is 524372's price volatile compared to industry and market?
524372 volatility
524372 Average Weekly Movement5.7%
Pharmaceuticals Industry Average Movement5.1%
Market Average Movement5.9%
10% most volatile stocks in IN Market9.2%
10% least volatile stocks in IN Market3.8%

Stable Share Price: 524372 is not significantly more volatile than the rest of Indian stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: 524372's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1992946Manish Dhanukahttps://www.orchidpharma.com

Orchid Pharma Limited, a pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India. Its active pharmaceutical ingredients product portfolio includes oral cephalosporins, injectable cephalosporins, veterinary products, and non-antibiotics. The company’s multi-therapeutic presence in anti-infectives, anti-inflammatory, central nervous system, cardiovascular segment, nutraceuticals, and other oral and sterile products, as well as offers new drug discovery systems and pharmaceutical research and development services.

Orchid Pharma Fundamentals Summary

How do Orchid Pharma's earnings and revenue compare to its market cap?
524372 fundamental statistics
Market Cap₹13.28b
Earnings (TTM)-₹471.37m
Revenue (TTM)₹5.98b

2.2x

P/S Ratio

-28.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
524372 income statement (TTM)
Revenue₹5.98b
Cost of Revenue₹3.49b
Gross Profit₹2.49b
Other Expenses₹2.96b
Earnings-₹471.37m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-11.55
Gross Margin41.65%
Net Profit Margin-7.88%
Debt/Equity Ratio41.4%

How did 524372 perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is 524372 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 524372?

Other financial metrics that can be useful for relative valuation.

524372 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2.7x
Enterprise Value/EBITDA27.1x
PEG Ration/a

Price to Sales Ratio vs Peers

How does 524372's PS Ratio compare to its peers?

524372 PS Ratio vs Peers
The above table shows the PS ratio for 524372 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average4x
507747 TTK Healthcare
2xn/a₹13.2b
532983 RPG Life Sciences
2.8xn/a₹13.0b
531146 Medicamen Biotech
10.2xn/a₹12.3b
500288 Morepen Laboratories
0.9xn/a₹13.9b
524372 Orchid Pharma
2.2xn/a₹13.3b

Price-To-Sales vs Peers: 524372 is good value based on its Price-To-Sales Ratio (2.2x) compared to the peer average (4x).


Price to Earnings Ratio vs Industry

How does 524372's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

Price-To-Sales vs Industry: 524372 is expensive based on its Price-To-Sales Ratio (2.2x) compared to the Indian Pharmaceuticals industry average (2x)


Price to Sales Ratio vs Fair Ratio

What is 524372's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

524372 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.2x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 524372's Price-To-Sales Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of 524372 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 524372 (₹325.45) is trading below our estimate of fair value (₹473.17)

Significantly Below Fair Value: 524372 is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is Orchid Pharma forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


18.8%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Orchid Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Examine whether Orchid Pharma is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
  • Orchid Pharma competitive advantages and company strategy can generally be found in its financial reports archived here.

Past Performance

How has Orchid Pharma performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


30.2%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 524372 is currently unprofitable.

Growing Profit Margin: 524372 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 524372 is unprofitable, but has reduced losses over the past 5 years at a rate of 30.2% per year.

Accelerating Growth: Unable to compare 524372's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 524372 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-2.1%).


Return on Equity

High ROE: 524372 has a negative Return on Equity (-7.28%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Orchid Pharma's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: 524372's short term assets (₹4.5B) exceed its short term liabilities (₹2.4B).

Long Term Liabilities: 524372's short term assets (₹4.5B) exceed its long term liabilities (₹2.2B).


Debt to Equity History and Analysis

Debt Level: 524372's net debt to equity ratio (40.7%) is considered high.

Reducing Debt: 524372 had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable 524372 has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: 524372 is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 44.7% per year.


Discover healthy companies

Dividend

What is Orchid Pharma current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Orchid Pharma Dividend Yield vs Market
How does Orchid Pharma dividend yield compare to the market?
SegmentDividend Yield
Company (Orchid Pharma)n/a
Market Bottom 25% (IN)0.4%
Market Top 25% (IN)1.6%
Industry Average (Pharmaceuticals)0.9%
Analyst forecast in 3 Years (Orchid Pharma)n/a

Notable Dividend: Unable to evaluate 524372's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 524372's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 524372's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 524372's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as 524372 has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average management tenure


CEO

Manish Dhanuka (55 yo)

2.58yrs

Tenure

₹7,335,289

Compensation

Shri. Manish Dhanuka serves as Director at Orchid Pharma Limited since March 31, 2020 and serves as its Managing Director since June 29, 2020. He has wide-range of experience of handling operations, commer...


CEO Compensation Analysis

Manish Dhanuka's Compensation vs Orchid Pharma Earnings
How has Manish Dhanuka's remuneration changed compared to Orchid Pharma's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022n/an/a

-₹471m

Mar 31 2022₹7m₹7m

-₹604m

Dec 31 2021n/an/a

-₹592m

Sep 30 2021n/an/a

-₹934m

Jun 30 2021n/an/a

-₹1b

Mar 31 2021₹5m₹5m

-₹952m

Compensation vs Market: Manish's total compensation ($USD90.14K) is below average for companies of similar size in the Indian market ($USD241.51K).

Compensation vs Earnings: Manish's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: 524372's management team is considered experienced (2.3 years average tenure).


Board Members

Experienced Board: 524372's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of 524372?
Owner TypeNumber of SharesOwnership Percentage
State or Government15,9420.04%
Institutions1,000,0002.4%
General Public2,358,4775.8%
Private Companies37,441,98191.7%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 4 shareholders own 91.77% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
89.96%
Dhanuka Laboratories Limited
36,719,957₹12.0b0%no data
1.77%
Aurigin Master Fund Limited
722,024₹235.0m0%no data
0.038%
India
15,375₹5.0m0%no data
0.0014%
Investor Education and Protection Fund (IEPF)
567₹184.5k0%no data

Company Information

Orchid Pharma Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Orchid Pharma Limited
  • Ticker: 524372
  • Exchange: BSE
  • Founded: 1992
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: ₹13.284b
  • Shares outstanding: 40.82m
  • Website: https://www.orchidpharma.com

Number of Employees


Location

  • Orchid Pharma Limited
  • Orchid Towers
  • No. 313, Valluvarkottam High Road
  • Chennai
  • Tamil Nadu
  • 600034
  • India


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ORCHIDPHARNSEI (National Stock Exchange of India)Old Equity SharesININRJul 1997
524372BSE (Mumbai Stock Exchange)YesEquity SharesININRNov 2020
ORCHPHARMANSEI (National Stock Exchange of India)YesEquity SharesININRNov 2020

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/10/05 00:00
End of Day Share Price2022/10/04 00:00
Earnings2022/06/30
Annual Earnings2022/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.